ZBIO
Zenas BioPharma, Inc. Common StockZBIO
ZBIO
About: Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
Employees: 130
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
150% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 14
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
49% more funds holding
Funds holding: 43 [Q3] → 64 (+21) [Q4]
13.78% more ownership
Funds ownership: 62.07% [Q3] → 75.85% (+13.78%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]
38% less capital invested
Capital invested by funds: $417M [Q3] → $260M (-$158M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
92%
upside
Avg. target
$32
225%
upside
High target
$45
354%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Wedbush Martin Fan 0% 1-year accuracy 0 / 2 met price target | 253%upside $35 | Outperform Initiated | 20 Mar 2025 |
Guggenheim Yatin Suneja 18% 1-year accuracy 6 / 34 met price target | 354%upside $45 | Buy Reiterated | 12 Mar 2025 |
HC Wainwright & Co. Matthew Caufield 22% 1-year accuracy 15 / 68 met price target | 202%upside $30 | Buy Reiterated | 12 Mar 2025 |
Wolfe Research Andy Chen 33% 1-year accuracy 5 / 15 met price target | 92%upside $19 | Outperform Initiated | 4 Feb 2025 |
Financial journalist opinion
Based on 78 articles about ZBIO published over the past 30 days
Neutral
Accesswire
1 hour ago
Zenas BioPharma, Inc. Class Action: Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
NEW YORK, NY / ACCESS Newswire / April 22, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144461&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
1 hour ago
Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses
WASHINGTON, April 22, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential securities fraud claims on behalf of investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) who acquired shares in the company's September 2024 initial public offering (“IPO”). The firm urges affected investors to contact the firm promptly to discuss their legal rights and recovery options.
Neutral
Accesswire
5 hours ago
Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
NEW YORK, NY / ACCESS Newswire / April 22, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144397&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
5 hours ago
ZBIO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas BioPharma" or "the Company") (NASDAQ:ZBIO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zenas BioPharma securities pursuant to the registration statement and prospectus issued in connection with the Company's September 13, 2024 initial public offering ("IPO").
Neutral
PRNewsWire
6 hours ago
Contact Levi & Korsinsky by June 16, 2025 Deadline to Join Class Action Against Zenas BioPharma, Inc.(ZBIO)
NEW YORK , April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud.
Neutral
Accesswire
15 hours ago
Shareholders that lost money on Zenas BioPharma, Inc.(ZBIO) should contact Levi & Korsinsky about pending Class Action - ZBIO
NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144370&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
15 hours ago
ZENAS BIOPHARMA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Zenas BioPharma, Inc. and Encourages Investors to Contact the Firm
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas BioPharma” or the “Company”) (NASDAQ:ZBIO) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering (the “Class Period”). Investors have until June 16, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Neutral
Accesswire
18 hours ago
Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144337&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
18 hours ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Neutral
Accesswire
18 hours ago
Zenas BioPharma, Inc. Class Action: Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144320&wire=1 or contact Joseph E. Levi, Esq.
Charts implemented using Lightweight Charts™